C
CURE51
Clinical and molecular database of exceptional survivors leading the path to new therapies against cancer
About CURE51
CURE51 is a French biotechnology company with a novel approach to cancer research, focusing on patients who have survived aggressive forms of the disease against all odds, termed "outliers." The company was co-founded by Nicolas Wolikow and Simon Istolainen, in collaboration with a consortium of five globally recognized oncology centers.
Read full description
The company is building a comprehensive global database of these cancer survivors, which already includes over 1,500 individuals from 42 countries. This database is populated through a proprietary data collection and discovery platform. In conjunction with this platform, CURE51 operates a dedicated central laboratory to conduct multi-omic sequencing of survivor samples. This integrated approach allows for the identification of robust therapeutic targets, which are then validated by a scientific community to pave the way for the development of new cancer drugs.
CURE51's initial focus is on three particularly aggressive types of cancer. The company plans to expand its research to other indications and therapeutic areas, leveraging its unique dataset and discovery pipelines. The business model appears to be centered on the discovery of new therapeutic targets, which can then be licensed to or co-developed with pharmaceutical partners, or developed in-house.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Paris, France
- Employees
- 62
- Open positions
- 1
- Dealroom signal
- 87.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Biotech and Pharma, AI Drug Discovery, biotech medtech and e-health, Observatoire Deeptech, Techbio
- Business model
- Marketplace & ecommerce, SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2024 | $17M | $66M | Xavier Niel · Hitachi Ventures · Sofinnova Partners · Olivier Pomel | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for CURE51 is 2.4K monthly website visits, down 14.3% over the last three months. CURE51's team grew 12.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Xavier Niel
Hitachi Ventures
Sofinnova Partners
Olivier Pomel
LifeX Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CURE51 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CURE51’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.